[{"orgOrder":0,"company":"Luminera","sponsor":"Innovative Luminera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved","graph3":"Luminera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable Gel","sponsorNew":"Luminera \/ Innovative Luminera","highestDevelopmentStatusID":"12","companyTruncated":"Luminera \/ Innovative Luminera"}]

Find Clinical Drug Pipeline Developments & Deals by Luminera

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.

                          Brand Name : HArmonyCa

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 07, 2020

                          Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Innovative Luminera

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank